康柏西普治疗脉络膜新生血管的临床研究

Clinical trial of Conbercept in the treatment of choroid neovascularization

目的探讨康柏西普治疗脉络膜新生血管的临床研究和对视网膜厚度的影响。方法按随机数表法将80例脉络膜新生血管患者分为试验组和对照组,每组40例。对照组予以雷珠单抗注射液治疗(于玻璃体腔内缓慢注射雷珠单抗注射液50μL),试验组予以康柏西普治疗(注入康柏西普50μL)。比较2组的临床疗效、最佳矫正视力、眼压、黄斑中心凹视网膜厚度(CMT),并观察2组的药物不良反应(ADR)发生率。结果治疗后,试验组和对照组总有效率分别为65. 00%,72. 50%;这2组的最佳矫正视力分别为0. 32±0. 05,0. 31±0. 03;这2组的眼压分别为(15. 38±2. 35),(14. 83±2. 24) mmHg;这2组的CMT分别为(259. 04±29. 12),(258. 86±27. 85)μm,组间比较差异均无统计学意义(均P> 0. 05)。2组的ADR发生率分别为20. 00%和17. 50%,组间比较差异无统计学意义(P> 0. 05)。结论康柏西普治疗脉络膜新生血管的短期效果和雷珠单抗相似,能够明显改善患者视力及视网膜厚度。

Objective To research the clinical effect of the Conbercept in the treatment of choroidal neovascularization and its influence on the retinal thickness. Methods Eighty cases of choroidal neovascularization patients was divided into control group and treatment group by the random table method（ n = 40）,control group was treated with licensed resistance（ slow injection of Ranibizumab Injections 50 μL in vitreous cavity）,treatment group was treated with Conbercept（ Injection of Conbercept 50μL）. Then clinical effect,best corrected visual acuity, intraocular pressure,macular foveal thickness（ CMT） were compared. And the incidence of adverse drug reaction（ ADR） in both group was observed.Results After treatment,the total effective rate in the treatment group and control group were 65. 00%,72. 50%; the best corrected visual acuity in the 2 groups were 0. 32 ± 0. 05,0. 31 ± 0. 03; the intraocular pressure in the 2 groups were（ 15. 38 ± 2. 35）,（ 14. 83 ± 2. 24） mmHg;CMT in the 2 groups were（ 259. 04 ± 29. 12）,（ 258. 86 ± 27. 85） μm,comparison between treatment group and control group,the differences of the factors without significantly（ all P〉0. 05）. The incidence of ADR in treatment group and control group was 20. 00% and 17. 50%,there was no difference between groups（ P〈0. 05）. Conclusion Short-term effects of Conbercept in treatment choroidal neovascularization is similar than the Rebezumab Injection, which can obviously improve the patients＇ vision and retinal thickness.